MedicalDevice Licensing.com
Pharmalicensing.com
Latest: Watch here for details of new products and services.
RSS Feeds
Advanced search

Login  Register

About Us
Pharmalicensing - Partnering solutions for the life sciences
 
Our Products
Overview
Partnering Search
Company Profiling
Deal Negotiation
PL Intelligence
Reports
Comparison
 
PL Intelligence
Overview
Industry news
Deals review
Press releases
Articles
 
Case Studies
See what others think about our service
 
Newsletter
Partnering update
Key reports
Subscribe
 
Quick Links
Profile now
Register now
Profiled companies
Featured events
Industry news
PR Newswire
Jobs
 
Contact Pharmalicensing
Send an email
Call us: +44 1904 520460
Request a callback
 
RSS Feeds
Keep up to date

Pharmalicensing
is a division of
UTEK Europe Ltd
UTEK Corporation
Out-licensing

COMPOSITIONS FOR IMPROVING SKIN CONDITIONS COMPRISING ALPHA-BISABOLOL AS AN ACTIVE INGRDIENT

Korea Health Industry Development Institute
Skin color is determined by concentration and distribution of melanin in the skin. A multitue of approaches and researches have been made to improve skin conditions but have finally failed to effectively improve them.

Mechanism of action

Notably multiple effects, Singificant reduction of melanin amounts, Scavenging ROS,Inhibition of COX

Full description

Technology Platform

The core technology of BioSpectrum is to provide promising skin-whitening agents.  The α-bisabolol exhibits improvements of skin-whitening and anti-wrinkle, inhibition of UV-irradiated hair loss, stimulation of hair growth and anti-obesity.

Background and unmet needs: Skin color is determined by the accumulation and distribution of melanin which functions to block skin damages caused from the UV irradiation. The activities of tyrosinase is important to the synthesis of melanin. Therefore, the regulation of the activities of tyrosinase is a critical point for skin color.

A multitue of approaches and researches have been made to improve skin conditions but not effectively.

Discovery and Achievements:  The α-bisabolol of BioSpectrum has been developed on the basis of findings that camomile has multiple effects such as anti-inflammation, sedative activities and pain relief and α-bisabolol is a main active component of camomile essence oil.

The α-bisabolol derived from camomile is very effective in improving skin-whitening, anti-wrinkle and anti-obesity. In addition, the α-bisabolol exhibits effects on inhibition of UV-irradiated hair loss and stimulation of hair growth.

The B16 murine melanoma (B-16 F10) was seeded into 6-well plate (1×105 per well) on DMEM and cultured at 37°C in 5% CO2 until above 80%. The α-bisabolol was treated to the samples at a concentration of 1 ppm, 5 ppm and 10 ppm and the samples were observed after 3 days of incubation. The amount of melanin per cells was measured at 490 nm using a microplate reader. The arbutin was served as a comparative agent.

Development status

Early Stage

Patent information

Nation

Appln. No

Status

Description

PCT

PCT/KR08/01141

Published

COMPOSITIONS FOR IMPROVING SKIN CONDITIONS COMPRISING ALPHA-BISABOLOL AS AN ACTIVE INGRDIENT

KOREA

2007-0019899

Granted

COMPOSITIONS FOR IMPROVING SKIN CONDITIONS COMPRISING ALPHA-BISABOLOL AS AN ACTIVE INGRDIENT

JAPAN

2009-501364

Pending

COMPOSITIONS FOR IMPROVING SKIN CONDITIONS COMPRISING ALPHA-BISABOLOL AS AN ACTIVE INGRDIENT

Type of business relationship sought

development collaboration, or non-exclusive or exclusive licensing agreement

Company details

Korea Health Industry Development Institute

KHIDI, provides various services on technology transfer. KHIDI will license and commercialise several technologies of KHIDI's client companies via collaboration with overseas partners.

View profile

Related reports

Are you looking for reports related to this particular subject. Our Reports section is the best place to start.

Related items

Related categories

Industry sector
Academic/Research
Therapeutic target
Allergy / Allergy, skin

Clients in focus...

Get the Flash Player to see this rotator.

Partnering discussion free of charge
BioPartnering America
Press releases: Pharmalicensing current industry press releases.

© Copyright 1995-2009 Pharmalicensing, a division of UTEK Europe Ltd UTEK Corporation All rights reserved. Terms and Conditions | Contact us